Floatz logo

ab-1015

Neoplasms, Glandular and Epithelial

Arsenal Biosciences, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Neoplasms, Glandular and Epithelial cohort.

Asset / SponsorPhaseRating
Sorafenib
Shandong Cancer Hospital and Institute
Phase 3BB
Catumaxomab
Neovii Biotech
Phase 2/3B
Pembrolizumab
Sheba Medical Center
Phase 2B
Enadenotucirev
Akamis Bio
Phase 1/2B
Linifanib
Abbott
Phase 3B

View all 36 →

Same molecule, other indications

ab-1015 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ovarian disorderDormant
CC
Indicative ·
43 / 100
View asset →
female reproductive system neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →